<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313443</url>
  </required_header>
  <id_info>
    <org_study_id>ATACA-URT04/06</org_study_id>
    <nct_id>NCT00313443</nct_id>
  </id_info>
  <brief_title>Concentrations of Amiodarone in Fat Tissue During Chronic Treatment</brief_title>
  <acronym>ATACA</acronym>
  <official_title>Study of Concentrations of Amiodarone in Fat Tissue Obtained by Needle Aspiration in Patients on Chronic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unité de Recherches Therapeutiques - H. Lariboisiere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if concentrations of amiodarone in fat tissue
      increases constantly over time during chronic treatment with this drug, and if blood
      concentrations reflect accurately the concentrations in fat tissue or not. This is because
      excessive concentrations of this drug in tissues can produce adverse effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amiodarone is very effective to treat cardiac arrhythmias but its use is limited by its
      toxicity, specially in chronic treatment. Accumulation of the drug in tissues is very
      probably the cause of the majority of amiodarone delayed adverse effects. However, this has
      not been proved because obtaining tissue samples is usually difficult and aggressive.

      The investigators study, in patients following chronic treatment with amiodarone, if needle
      aspiration can provide samples of fat tissue useful to accurately determine amiodarone
      concentrations, how those concentrations in fat tissue correlate with cumulated dose, and how
      concentrations in fat tissue correlate with concentrations in blood, which is easier to
      obtain.

      The investigators expect this knowledge will help to understand how amiodarone develops its
      adverse effects and possibly lead to new ways of monitoring treatment with this drug, or to
      adapt doses in chronic administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose.</measure>
    <time_frame>One single measure</time_frame>
    <description>Correlation between amiodarone concentration in fat tissue (mean from several sampling points) and cumulated dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship Between Amiodarone Concentrations in Fat Tissue and in Plasma.</measure>
    <time_frame>One single measure, taken just before daily administration</time_frame>
    <description>Correlation between amiodarone concentrations in fat tissue (mean of 2 samples) and simultaneous concentration in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship Between Amiodarone Concentrations in Fat Tissue and Developing Adverse Effects.</measure>
    <time_frame>Cumulated time on amiodarone (varies in each patient)</time_frame>
    <description>Relationship between amiodarone concentrations in fat tissue (mean of two different samplings and developping adverse effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and Complications (if Any) Caused by Fat Tissue Needle Aspirations</measure>
    <time_frame>24 hours after needle aspiration</time_frame>
    <description>Number of patients having complications (if any) caused by fat tissue needle aspirations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Any Adverse Effect Attributable to Amiodarone.</measure>
    <time_frame>Cumulated time on amiodarone (varies in each patient)</time_frame>
    <description>Number of patients developing adverse effects by amiodarone leading to withdrawal or specific treatment (i.e. thyroid hormone treatment)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Amiodarone, long-term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fat tissue needle aspiration</intervention_name>
    <description>Small fat tissue sampling performed by needle aspiration.</description>
    <arm_group_label>Amiodarone, long-term</arm_group_label>
    <other_name>Adipose subcutaneous tissue biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients taking amiodarone for more than 3 months (any dose, any indication)

        Exclusion Criteria:

          -  Impossibility to perform needle aspiration of abdominal wall (local infection, skin
             disease)

          -  Coagulation disorders, INR &gt; 3.0 if warfarin treatment

          -  Patient unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmelo Lafuente-Lafuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Lariboisière, Internal Medicine &quot;A&quot; Service, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Bergmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Lariboisiere, Internal Medicine &quot;A&quot; Service, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Lariboisiere, Internal Medicine &quot;A&quot; and Cardiology Services</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2006</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>August 4, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2009</results_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Carmelo Lafuente-Lafuente</name_title>
    <organization>Unité de Recherches Therapeutiques. Hopital Lariboisiere.</organization>
  </responsible_party>
  <keyword>Anti-Arrhythmia Agents</keyword>
  <keyword>Amiodarone, chronic treatment</keyword>
  <keyword>Amiodarone, adverse effects</keyword>
  <keyword>Biopsy, Fine-Needle, Adipose tissue</keyword>
  <keyword>Drug concentrations in tissues</keyword>
  <keyword>Drug accumulation in tissues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at a teaching hospital, from July 2006 to October 2007.</recruitment_details>
      <pre_assignment_details>67 consecutive patients were evaluated and 30 patients included. Reasons for non inclusion were: impossible to retrace history of amiodarone administration: 19 patients; less than 3 months on amiodarone treatment: 10 patients; unable to give informed consent: 4 patients; refused to participate: 4 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amiodarone/Fat Tissue Needle Aspiration</title>
          <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amiodarone/Fat Tissue Needle Aspiration</title>
          <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose.</title>
        <description>Correlation between amiodarone concentration in fat tissue (mean from several sampling points) and cumulated dose.</description>
        <time_frame>One single measure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone/Fat Tissue Needle Aspiration</title>
            <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose.</title>
          <description>Correlation between amiodarone concentration in fat tissue (mean from several sampling points) and cumulated dose.</description>
          <units>Correlation coefficient R</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relationship Between Amiodarone Concentrations in Fat Tissue and in Plasma.</title>
        <description>Correlation between amiodarone concentrations in fat tissue (mean of 2 samples) and simultaneous concentration in plasma.</description>
        <time_frame>One single measure, taken just before daily administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone/Fat Tissue Needle Aspiration</title>
            <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Amiodarone Concentrations in Fat Tissue and in Plasma.</title>
          <description>Correlation between amiodarone concentrations in fat tissue (mean of 2 samples) and simultaneous concentration in plasma.</description>
          <units>Correlation coefficient R</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relationship Between Amiodarone Concentrations in Fat Tissue and Developing Adverse Effects.</title>
        <description>Relationship between amiodarone concentrations in fat tissue (mean of two different samplings and developping adverse effects.</description>
        <time_frame>Cumulated time on amiodarone (varies in each patient)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone/Fat Tissue Needle Aspiration</title>
            <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Amiodarone Concentrations in Fat Tissue and Developing Adverse Effects.</title>
          <description>Relationship between amiodarone concentrations in fat tissue (mean of two different samplings and developping adverse effects.</description>
          <units>Logistic regression OR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain and Complications (if Any) Caused by Fat Tissue Needle Aspirations</title>
        <description>Number of patients having complications (if any) caused by fat tissue needle aspirations</description>
        <time_frame>24 hours after needle aspiration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone/Fat Tissue Needle Aspiration</title>
            <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
          </group>
        </group_list>
        <measure>
          <title>Pain and Complications (if Any) Caused by Fat Tissue Needle Aspirations</title>
          <description>Number of patients having complications (if any) caused by fat tissue needle aspirations</description>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Any Adverse Effect Attributable to Amiodarone.</title>
        <description>Number of patients developing adverse effects by amiodarone leading to withdrawal or specific treatment (i.e. thyroid hormone treatment)</description>
        <time_frame>Cumulated time on amiodarone (varies in each patient)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone/Fat Tissue Needle Aspiration</title>
            <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Any Adverse Effect Attributable to Amiodarone.</title>
          <description>Number of patients developing adverse effects by amiodarone leading to withdrawal or specific treatment (i.e. thyroid hormone treatment)</description>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amiodarone/Fat Tissue Needle Aspiration</title>
          <description>Unique arm: all patients underwent amiodarone dosage in blood and fat tissue samplings</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local Complications (if Any) Caused by Fat Tissue Needle Aspirations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients included. High variability of amiodarone concentrations in fat tissue between the 2 simultaneous samples for some patients. Incidence of amiodarone-related adverse effects probably overestimated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Carmelo Lafuente-Lafuente</name_or_title>
      <organization>Unité de Recherches Thérapeutiques. Service de Médecine Interne A. Hôpital Lariboisière. Paris, France</organization>
      <phone>+33 1 49 95 63 37</phone>
      <email>c.lafuente@nodo3.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

